{
    "nctId": "NCT04190433",
    "briefTitle": "Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial",
    "officialTitle": "AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR) Trial",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Sarcoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Delta change in left ventricular ejection fraction [LVEF])",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* \\>= 18 years of age.\n* New diagnosis of reduced cardiac function.\n* Any prior anthracycline-based cancer therapy for hematological malignancy, breast cancer, or sarcoma.\n\nExclusion Criteria:\n\n* History of heart failure (HF) of any class and type, or diagnosis of cardiomyopathy prior to anthracycline therapy.\n* On active therapy with a fibrate, niacin or eplerenone, or statin.\n* History of myopathy/rhabdomyolysis.\n* History of statin intolerance.\n* Active treatment for hyperlipidemia.\n* History of gout.\n* Active treatment for liver disease.\n* Unexplained persistent elevations of serum transaminases (above upper limit of normal over two weeks).\n* Pregnancy.\n* Breast-feeding.\n* Hyperkalemia (above upper limit of normal).\n* Addison disease.\n* Estimated glomerular filtration rate (eGFR) \\< 30 mL/minute/1.73 m\\^2.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}